Strongbridge Biopharma

Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.

DUBLIN, Ireland and TREVOSE, Pa., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has approved inducement equity awards to ten individuals who have recently become, or are expected to become, employees of the Company.

Strongbridge Biopharma plc Announces New Employment Inducement Awards

~ Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase over 2019 Revenue of $ $21.7 Million ~

Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update

~ RECORLEV™ (levoketoconazole) Treatment Resulted in Significantly Improved Clinician-Assessed Signs and Symptoms and Patient-Reported Outcomes of Cushing's Syndrome ~ ~ RECORLEV™ (levoketoconazole) Treatment Resulted in Significantly Improved Clinician-Assessed Signs and Symptoms and Patient-Reported Outcomes of Cushing's Syndrome ~

Strongbridge Biopharma plc Announces Publication of Secondary Endpoints Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing's Syndrome in the Journal, Pituitary

The shares of small-cap biopharma concern are finally seeing some momentum as they rally off oversold levels. The company posted better-than-expected Q3 results in late October and have some potential catalysts on the horizon in 2021.

Strongbridge Biopharma: $2.50 Biotech Stock Finally Seeing Some Momentum

DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will participate in fireside chats at the Stifel and Jefferies 2020 Virtual Healthcare Conferences.

Strongbridge Biopharma plc Announces Participation in Two Upcoming Investor Conferences

Strongbridge Biopharma plc (SBBP) CEO John Johnson on Q3 2020 Results - Earnings Call Transcript

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 20.00% and 11.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Strongbridge Biopharma (SBBP) Reports Q3 Loss, Tops Revenue Estimates

~ Company on Track to Submit New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in the First Quarter of 2021 Following the Reporting of Positive Top-line Data from the LOGICS Study in the Third Quarter of 2020 ~

Strongbridge Biopharma plc Reports Third Quarter 2020 Financial Results and Provides Corporate Update

DUBLIN, Ireland and TREVOSE, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will host a conference call with members of Strongbridge's management team on Thursday, October 29 at 4:30 p.m. ET to discuss the Company's third quarter 2020 financial results and to provide a business update. The conference call will follow the anticipated release of the Company's financial results earlier that day.

Strongbridge Biopharma plc to Host Third Quarter 2020 Financial Results Conference Call on October 29, 2020

DUBLIN, Ireland and TREVOSE, Pa., Sept.  16, 2020  (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has priced its previously announced underwritten public offering.  The Company is offering 11,111,111 ordinary shares at a price to the public of $2.25 per share for total gross proceeds of approximately $25.0 million, before deducting the underwriting discount and estimated offering expenses payable by the Company. The offering is expected to close on or about September 21, 2020, subject to the satisfaction of customary closing conditions. In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 1,666,666 ordinary shares on the same terms and conditions.

Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares

DUBLIN, Ireland and TREVOSE, Pa., Sept.  16, 2020  (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it intends to offer and sell ordinary shares in an underwritten public offering. The Company also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering.

Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Strongbridge Biopharma plc ("Strongbridge" or the "Company") (NYSE: SBBP).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Strongbridge Biopharma plc - SBBP

After reporting positive Recorlev Phase 3 top line data, SBBP management demonstrated incredible confidence by guiding investors to expect $250MM-$350MM/year in peak Recorlev sales/year.

Strongbridge Appears An Incredible Value After Releasing Recorlev's Phase 3 Data

~ Company Reported Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome; To View the Complete Earlier Announcement, Visit the Company’s Website ~

Strongbridge Biopharma plc Provides Corporate Update

~ LOGICS Study Met Primary Endpoint with High Statistical Significance; Results at the End of the Randomized-Withdrawal Phase of the Study Demonstrated that Withdrawing Patients to Placebo Resulted in a Loss of Cortisol Response in 54.5 Percent (p=0.0002) More Patients than the RECORLEV® (levoketoconazole) Arm ~

Strongbridge Biopharma plc Announces Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome

Recorlev's Cushing's disease phase 3 topline data is due 9/2020. If the data looks good, NDA submission follows. If the data does not look good, SBBP options are very limited.

Strongbridge Biopharma's Recorlev Phase 3 Topline Data Due September 2020 Is A Major Value Inflection Point

Strongbridge Biopharma plc's (SBBP) CEO John Johnson on Q2 2020 Results - Earnings Call Transcript

~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2020 Revenue of $7.8 Million, a 28 Percent Increase Compared to $6.1 Million During Second Quarter of 2019 ~

Strongbridge Biopharma plc Reports Second Quarter 2020 Financial Results and Provides Corporate Update

DUBLIN, Ireland and TREVOSE, Pa., July  28, 2020  (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will host a conference call with members of Strongbridge’s management team on Tuesday, August 4 at 8:30 a.m. ET to discuss the Company’s second quarter 2020 financial results and to provide a business update. The conference call will follow the anticipated release of the Company’s financial results earlier that day.

Strongbridge Biopharma plc to Host Second Quarter 2020 Financial Results Conference Call on August 4, 2020

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Strongbridge Biopharma (SBBP) Report Negative Q2 Earnings? What You Should Know

DUBLIN, Ireland and TREVOSE, Pa., July  07, 2020  (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that at the request of the Board of Directors, John H. Johnson has agreed to become the chief executive officer (CEO) of Strongbridge.  

Strongbridge Biopharma plc Announces Appointment of John H. Johnson to  Chief Executive Officer

Company Expects to Report Topline Phase 3 LOGICS Study Results During the Third Quarter of 2020 Company Expects to Report Topline Phase 3 LOGICS Study Results During the Third Quarter of 2020

Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome

DUBLIN, Ireland and TREVOSE, Pa., May  20, 2020  (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it and its subsidiaries have entered into a $30 million debt facility with Avenue Venture Opportunities Fund, L.P. (Avenue), a fund within the Avenue Capital Group, and its affiliates.

Strongbridge Biopharma plc Announces $30 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.

Strongbridge Biopharma Attractive Valuation With Catalysts Approaching

Company Expects to Report Top-Line LOGICS Results During the Third Quarter of 2020 Company Expects to Report Top-Line LOGICS Results During the Third Quarter of 2020

Strongbridge Biopharma plc Announces Completion of Enrollment of Phase 3 LOGICS Study for RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome

News for Strongbridge Biopharma Stock (SBBP)